Pharmaceutical

Eikon raises almost $351m to advance cancer candidates through the clinic

Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.

Feb 27, 2025 - 06:00
Eikon raises almost $351m to advance cancer candidates through the clinic
Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.
Read the original article

Tags:

Previous Article

Magazine: Radiopharmaceutical deals drive sector growth despite supply crisis

Next Article

Emalex eyes FDA approval for Tourette syndrome therapy after Phase III success

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Most of Canada’s public research universities get bad grades for ensuring access to drugs they discover

STAT+: Most of Canada’s public research universities ge...

May 1, 2023

Opinion: Bloated patient records are filled with false information, thanks to copy-paste

Opinion: Bloated patient records are filled with false ...

Jun 20, 2023

Finding the right solution and partner for your drug product’s commercial supply chain

Finding the right solution and partner for your drug pr...

Jul 18, 2024